Inspira Technologies announces Inspira ART100 system completed evaluation

Inspira Technologies (IINN) announced that its U.S. Food and Drug Administration-cleared INSPIRA ART100 system has completed its full clinical evaluation and advanced to a budgeted procurement execution process at a leading U.S. academic medical center. Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, commented: “We view reaching this milestone at one of the nation’s leading academic medical centers as a powerful validation of our technology’s clinical value and reliability. The ART100 has moved beyond pilot use to standard clinical workflow, driven by repeat utilization and positive physician feedback. With the clinical phase now complete, we are advancing through a defined procurement execution process and view this milestone as a strong validation of our ART100’s real-world clinical and commercial readiness.”